CLBS Caladrius Biosciences Inc.

2.96
-0.07  -2%
Previous Close 3.03
Open 3
Price To Book 0.89
Market Cap 30731407
Shares 10,382,232
Volume 17,981
Short Ratio
Av. Daily Volume 30,011

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data did not meet primary endpoint - February 13, 2019.
CLBS03 (The Sanford Project T-Rex Study)
Type 1 diabetes
Announced January 2016 that Phase 3 trial has been discontinued
CLBS20
Metastatic melanoma
Phase 2 data due by the end of 2019.
CLBS14-CMD
Coronary microvascular dysfunction (CMD)
Phase 3 trial to be initiated by the end of 2019.
CLBS14-NORDA
Angina
Phase 2 data due 1H 2020.
CLBS12
Critical Limb Ischemia (CLI)

Latest News

  1. Edited Transcript of CLBS earnings conference call or presentation 9-May-19 8:30pm GMT
  2. Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update
  3. Caladrius Biosciences to Participate at the Upcoming May Conferences
  4. Caladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time
  5. How Does Caladrius Biosciences, Inc. (NASDAQ:CLBS) Affect Your Portfolio Volatility?
  6. Caladrius Biosciences to Participate in Upcoming Conferences
  7. Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results
  8. Caladrius Biosciences announces Purchase Agreement with Lincoln Park Capital for up to $26 million
  9. Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time
  10. What Kind Of Shareholder Appears On The Caladrius Biosciences, Inc.’s (NASDAQ:CLBS) Shareholder Register?
  11. Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day
  12. Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes
  13. Caladrius Biosciences to Present at Upcoming February Conferences
  14. What Makes Caladrius Biosciences (CLBS) a New Buy Stock
  15. Caladrius Biosciences to Participate in Upcoming January Conferences
  16. Recent Analysis Shows Escalade, Caladrius Biosciences, LightInTheBox Holding Co., Vishay Intertechnology, Ceridian HCM Holding, and Avista Market Influences — Renewed Outlook, Key Drivers of Growth
  17. Caladrius Biosciences to Participate in the Inv€$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London Healthcare Conference
  18. Caladrius Biosciences Reports 2018 Third Quarter Financial Results
  19. Caladrius Biosciences Appoints Cynthia Schwalm to Board of Directors
  20. Caladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET